Use of the Stanford Health Assessment Questionnaire in estimation of long‐term productivity costs in patients with recent‐onset rheumatoid arthritis

References

• van der Heide A., Jacobs J. W. G., van Albada‐Kuipers G. A., Kraaimaat F. W., Geenen R., Bijlsma J. W. J. Physical disability and psychological well‐being in recent onset rheumatoid arthritis. J Rheumatol 1994; 21: 28–32
   PubMed Web of Science ®Google Scholar
• Griffith J., Carr A. What is the impact of early rheumatoid arthritis on the individual?. Best Pract Res Clin Rheumatol 2001; 15: 77–90
   PubMed Web of Science ®Google Scholar
• Sørensen J. Healthcare costs attributable to the treatment of rheumatoid arthritis. Scand J Rheumatol 2004; 33: 399–404
   PubMed Web of Science ®Google Scholar
• Yelin E. The costs of rheumatoid arthritis: absolute, incremental, and marginal estimates. J Rheumatol 1996; 23((Suppl 44))47–51
   Google Scholar
• Pugner K. M., Scott D. I., Holmes J. W., Hieke K. The costs of rheumatoid arthritis: an international long‐term view. Semin Arthritis Rheum 2000; 29: 305–20
   PubMed Web of Science ®Google Scholar
• Newhall‐Perry K., Law N. J., Ramos B., Sterz M., Wong W. K., Bulpitt K. J., et al. Direct and indirect costs associated with the onset of seropositive rheumatoid arthritis. Western Consortium of Practicing Rheumatologists. J Rheumatol 2000; 27: 1156–63
   PubMed Web of Science ®Google Scholar
• Merkesdal S., Ruof J., Schoffski O., Bernitt K., Zeidler H., Mau W. Indirect medical costs in early rheumatoid arthritis: composition of and changes in indirect costs within the first three years of disease. Arthritis Rheum 2001; 44: 528–34
   PubMed Web of Science ®Google Scholar
• Sokka T. Work disability in early rheumatoid arthritis. Clin Exp Rheumatol 2003; 21((Suppl 3)1)71–4
   PubMed Web of Science ®Google Scholar
• Verstappen S. M., Bijlsma J. W., Verkleij H., Buskens E., Blaauw A. A., ter Borg E. J., , Utrecht Rheumatoid Cohort Study Group, et al. Overview of work disability in rheumatoid arthritis patients as observed in cross‐sectional and longitudinal surveys. Arthritis Rheum 2004; 51: 488–97
   PubMed Web of Science ®Google Scholar
• Burton W., Morrison A., Maclean R., Ruderman E. Systematic review of studies of productivity loss due to rheumatoid arthritis. Occup Med (Lond) 2006; 56: 18–27
   PubMed Web of Science ®Google Scholar
• Hallert E., Husberg M., Skogh T. Costs and course of disease and function in early rheumatoid arthritis: a 3‐year follow‐up (the Swedish TIRA project). Rheumatology (Oxford) 2006; 45: 325–31
   PubMed Web of Science ®Google Scholar
• Puolakka K., Kautiainen H., Pekurinen M., Möttönen T., Hannonen P., Korpela M., et al. Monetary value of lost productivity over a five year follow up in early rheumatoid arthritis estimated on the basis of official register data on patients' sickness absence and gross income: experience from the FIN‐RACo trial. Ann Rheum Dis 2006; 65: 899–904
   PubMed Web of Science ®Google Scholar
• Kobelt G. Health economic issues in rheumatoid arthritis. Scand J Rheumatol 2006; 35: 415–25
   PubMed Web of Science ®Google Scholar
• Fries J., Spitz P., Kraines R., Holman H. Measurement of patient outcome in arthritis. Arthritis Rheum 1980; 23: 137–45
   PubMed Web of Science ®Google Scholar
• Yelin E., Meenan R., Nevitt M., Epstein W. Work disability in rheumatoid arthritis: effects of disease, social, and work factors. Ann Intern Med 1980; 93: 551–6
   PubMed Web of Science ®Google Scholar
• Sokka T., Pincus T. Markers for work disability in rheumatoid arthritis. J Rheumatol 2001; 28: 1718–22
   PubMed Web of Science ®Google Scholar
• de Croon E. M., Sluiter J. K., Nijssen T. F., Dijkmans B. A., Lankhorst G. J., Frings‐Dresen M. H. Predictive factors of work disability in rheumatoid arthritis: a systematic literature review. Ann Rheum Dis 2004; 63: 1362–7
   PubMed Web of Science ®Google Scholar
• Puolakka K., Kautiainen H., Möttönen T., Hannonen P., Hakala M., Korpela M., et al. Predictors of productivity loss and work disability in early rheumatoid arthritis: a 5‐year followup study. Ann Rheum Dis 2005; 64: 130–3
   PubMed Web of Science ®Google Scholar
• Bathon J. M., Martin R. W., Fleischmann R. M., Tesser J. R., Schiff M. H., Keystone E. C., et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000; 343: 1586–93
   PubMed Web of Science ®Google Scholar
• Puolakka K., Kautiainen H., Möttönen T., Hannonen P., Korpela M., Hakala M., et al. Early suppression of disease activity is essential for maintenance of work capacity in patients with recent‐onset rheumatoid arthritis: five‐year experience from the FIN‐RACo trial. Arthritis Rheum 2005; 52: 36–41
   PubMed Web of Science ®Google Scholar
• Kobelt G., Eberhardt K., Jonsson L., Jonsson B. Economic consequences of the progression of rheumatoid arthritis in Sweden. Arthritis Rheum 1999; 42: 347–56
   PubMed Web of Science ®Google Scholar
• Kavanaugh A., Han C., Bala M. Functional status and radiographic joint damage are associated with health economic outcomes in patients with rheumatoid arthritis. J Rheumatol 2004; 31: 849–55
   PubMed Web of Science ®Google Scholar
• Kobelt G., Jonsson L., Lindgren P., Young A., Eberhardt K. Modeling the progression of rheumatoid arthritis. A two‐country model to estimate costs and consequences of rheumatoid arthritis. Arthritis Rheum 2002; 46: 2310–19
   PubMed Web of Science ®Google Scholar
• Jacobsson L. T., Lindroth Y., Marsal L., Juran E., Bergstrom U., Kobelt G. Rheumatoid arthritis: what does it cost and what factors are driving those costs? Results of a survey in a community‐derived population in Malmö, Sweden. Scand J Rheumatol 2007; 36: 179–83
   PubMed Web of Science ®Google Scholar
• Hedin P. J., McKenna S. P., Meads D. M. The Rheumatoid Arthritis Quality of Life (RAQoL) for Sweden: adaptation and validation. Scand J Rheumatol 2006; 35: 117–23
   PubMed Web of Science ®Google Scholar
• Rupp I., Boshuizen H. C., Dinant H. J., Jacobi C. E., van den Bos G. A. Disability and health‐related quality of life among patients with rheumatoid arthritis: association with radiographic joint damage, disease activity, pain, and depressive symptoms. Scand J Rheumatol 2006; 35: 175–81
   PubMed Web of Science ®Google Scholar
• Bansback N. J., Regier D. A., Ara R., Brennan A., Shojania K., Esdaile J. N., et al. An overview of economic evaluations for drugs used in rheumatoid arthritis: focus on tumour necrosis factor‐alpha antagonists. Drugs 2005; 65: 473–96
   PubMed Web of Science ®Google Scholar
• Eberhardt K., Fex E. Clinical course and remission rate in patients with early rheumatoid arthritis: relationship to outcome after 5 years. Br J Rheumatol 1998; 37: 1324–9
   PubMedGoogle Scholar
• Young A., Dixey J., Cox N., Davies P., Devlin J., Emery P., et al. How does functional disability in early rheumatoid arthritis (RA) affect patients and their lives? Results of 5 years of follow‐up in 732 patients from the Early RA Study (ERAS). Rheumatology (Oxford) 2000; 39: 603–11
   PubMed Web of Science ®Google Scholar
• Mottonen T., Hannonen P., Leirisalo‐Repo M., Nissila M., Kautiainen H., Korpela M., et al. Comparison of combination therapy with single‐drug therapy in early rheumatoid arthritis: a randomised trial. FIN‐RACo trial group. Lancet 1999; 353: 1568–73
   PubMed Web of Science ®Google Scholar
• Korpela M., Laasonen L., Hannonen P., Kautiainen H., Leirisalo‐Repo M., Hakala M., et al. Retardation of joint damage in patients with early rheumatoid arthritis by initial aggressive treatment with disease‐modifying antirheumatic drugs: five‐year experience from the FIN‐RACo study. Arthritis Rheum 2004; 50: 2072–81
   PubMed Web of Science ®Google Scholar
• Felson D. T., Anderson J. J., Boers M., Bombardier C., Chernoff M., Fried B., et al. The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. The Committee on Outcome Measures in Rheumatoid Arthritis Clinical Trials. Arthritis Rheum 1993; 36: 729–40
   PubMed Web of Science ®Google Scholar
• Koopmanschap M. A., Rutten F. F. A practical guide for calculating indirect costs of disease. Pharmacoeconomics 1996; 10: 460–6
   PubMed Web of Science ®Google Scholar
• Koopmanschap M. A., Rutten F. F., van Ineveld B. M., van Roijen L. The friction cost method for measuring indirect costs of disease. J Health Econ 1995; 14: 171–89
   PubMed Web of Science ®Google Scholar
• Ministry of Labour of Finland, Statistics on vacancies 1993 to 2000. www.mol.fi
   Google Scholar
• Hakala M., Nieminen P., Manelius J. Joint impairment is strongly correlated with disability measured by self‐reported questionnaires. Functional status assessment on individuals with rheumatoid arthritis in a population based series. J Rheumatol 1994; 21: 64–9
   PubMed Web of Science ®Google Scholar
• Goekoop‐Ruiterman Y. P., de Vries‐Bouwstra J. K., Allaart C. F., van Zeben D., Kesrtens P. J., Hazes J. M., et al. Comparison of treatment strategies in early rheumatoid arthritis: a randomized trial. Ann Intern Med 2007; 146: 406–15
   PubMed Web of Science ®Google Scholar
• Eberhardt K., Larsson B. M., Nived K. Early rheumatoid arthritis: some social, economical, and psychological aspects. Scand J Rheumatol 1993; 22: 119–23
   PubMed Web of Science ®Google Scholar
• Kobelt G., Lindgren P., Lindroth Y., Jacobson L., Eberhardt K. Modelling the effect of function and disease activity on costs and quality of life in rheumatoid arthritis. Rheumatology (Oxford) 2005; 44: 1169–75
   PubMed Web of Science ®Google Scholar
• Kobelt G., Lindgren P., Singh A., Klareskog L. Cost effectiveness of etanercept (Enbrel) in combination with methotrexate in the treatment of active rheumatoid arthritis based on the TEMPO trial. Ann Rheum Dis 2005; 64: 1174–9
   PubMed Web of Science ®Google Scholar
• Verstappen S. M., Boonen A., Verkleij H., Bijlsma J. W., Buskens E., Jacobs J. W. Productivity costs among patients with rheumatoid arthritis: the influence of methods and sources to value loss of productivity. Ann Rheum Dis 2005; 64: 1754–60
   PubMed Web of Science ®Google Scholar
• Johannesson M., Karlsson G. The friction cost method: a comment. J Health Econ 1997; 16: 249–55
   PubMed Web of Science ®Google Scholar
• Confederation of Finnish Industries, Sickness absences in Industry. www.ek.fi
   Google Scholar
• Puolakka K., Kautiainen H., Mottonen T., Hannonen P., Korpela M., Julkunen H., et al. Impact of initial aggressive drug treatment with a combination of disease‐modifying antirheumatic drugs on the development of work disability in early rheumatoid arthritis: a five‐year randomized followup trial. Arthritis Rheum 2004; 50: 55–62
   PubMed Web of Science ®Google Scholar
• Chung C. P., Sokka T., Arbogast P. G., Pincus T. Work disability in early rheumatoid arthritis: higher rates but better clinical status in Finland compared with the US. Ann Rheum Dis 2006; 65: 1653–7
   PubMed Web of Science ®Google Scholar
• Stewart W. F., Ricci J. A., Chee E., Morganstein D., Lipton R. Lost productive time and cost due to common pain conditions in the US workforce. J Am Med Assoc 2003; 290: 2443–54
   PubMed Web of Science ®Google Scholar
• Wang P. S., Beck A., Berglund P., Leutzinger J. A., Pronk N., Richling D., et al. Chronic medical conditions and work performance in the health and work performance questionnaire calibration surveys. J Occup Environ Med 2003; 45: 1303–11
   PubMed Web of Science ®Google Scholar